# RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction

> **NCT07166380** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Neurodawn Pharmaceutical Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Transcranial Bone Marrow Injection
- RK-4
- Acute Large Hemispheric Infarction
- Acute Ischemic Stroke

## Interventions

- **DRUG:** RK-4 injection

## Key facts

- **NCT ID:** NCT07166380
- **Lead sponsor:** Neurodawn Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-20
- **Primary completion:** 2026-02-20
- **Final completion:** 2026-05-19
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166380, "RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT07166380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*